[BidClub_]

SHOW DIRECTORY

Sourcery

Molly O'Shea interviews leading investors, CEOs, and founders about technology companies, markets, and company building.

SOURCE DESCRIPTION · RSS

41 EPISODESENTRACKED SHOW
SUBSCRIBE[Feed_]
14 episodes2 active
Language
SourceryEN · 56 min

Apollo’s Yahoo Playbook, 5 Years After the $5B Deal

Jim LanzoneMolly O'Shea

Lanzone says Apollo has largely recovered its $4.8 billion Yahoo cost through early cash returns and disposals including AOL.The reset shut loss-making ad tech that cost hundreds of millions annually and opened inventory to competing demand, while retaining DSP.Scout restores owned search, but Lanzone makes no IPO commitment and hesitates to call Yahoo’s audience distribution a moat.

SourceryEN · 70 min

Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX

Molly O'SheaNworah Ayogu

Thrive’s healthcare thesis is that AI may shift bottlenecks from molecule generation to validation, trials, manufacturing, and commercialization.Cadence cites 25% fewer hospitalizations, over-80% more controlled-blood-pressure patients, nearly one-point lower A1C, and $2.5 million in weekly Medicare savings across 100,000+ monitored patients.Neuralink and OpenAI show upside, while clinical processes and manufacturing capacity remain unresolved constraints.

SourceryEN · 85 min

USV’s New $900M Fund: Fred Wilson, Rebecca Kaden & Mike Mignano

Fred WilsonRebecca KadenMichael MignanoMolly O'Shea

USV’s $900 million fund targets 30-40 companies with $10 million-$30 million Series A checks as larger rounds and scaling costs reshape venture.Its AI thesis spans applications, infrastructure, physical AI, and energy, while usage retention, compute costs, inference subsidies, distribution, interoperability, trust, and leadership concentration remain key tests.

SourceryEN · 58 min

Annie Lamont: $14B Managed, 70+ Exits, 15 IPOs, 7x Midas Investor

Jonathan SiddharthMolly O'Shea

Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.

SourceryEN · 22 min

The $500B Opportunity in Europe’s Defense Buildout

Molly O'SheaAistis ŠimaitisGeorge HadjiminasBruno Wejchert

Ukraine has made production scale as important as technology: Europe’s fragmented manufacturing base and years-long component lead times leave a clear opening for Onodrim’s acquisition-led model.Autonomous fleets also reset unit economics, turning $30,000 radios and other exquisite components into products that must become cheaper and available in thousands or millions; execution and procurement remain the watchpoints.

SourceryEN · 48 min

Eclipse's Lior Susan on $12.5B AUM and the Bet on Physical Industries

Molly O'SheaLior Susan

Eclipse is targeting the physical economy—about 85% of global GDP, or $100 trillion—where deglobalization, supply-chain vulnerability, government support, and customer demand are reopening neglected opportunities.With about $12.5 billion in AUM, roughly 90 portfolio companies, and 30 it helped build, its operators-with-capital model links CapEx, manufacturing, policy, and systems execution, while its free-cash-flow focus and non-formulaic incubation leave execution, timing, and repeatability as key variables.

SourceryEN · 75 min

Bending Spoons Is Coming for Silicon Valley, with CEO Luca Ferrari

Luca FerrariMolly O'Shea

Bending Spoons’ edge is an integrated operating model that standalone owners cannot economically reproduce.Its 50-plus proprietary technologies, nearly 1,000-person core team, and debt-funded permanent ownership support claimed annual savings above $100 million and $4 million revenue per core Spooner.Airtable’s approximately $1.3 billion enterprise value reflects the underwriting test, while AI startup valuations and unmeasured AI capabilities remain key risks to monitor.

SourceryEN · 78 min

Bending Spoons Founders on Buying Airtable, AOL, Vimeo & Miro

Molly O'SheaLuca FerrariFrancesco PatarnelloMatteo DanieliValentina Jerusalmi

Bending Spoons wins deals by paying the highest price, with post-integration platform, technology, and talent value supporting high returns for shareholders.Its vertical-agnostic filter prioritizes platform unlock, sufficient scale, and predictability, favoring 5–10 larger deals over transforming $20 million-revenue businesses.With an M&A pipeline that has never been so rich, AOL’s months-long Yahoo carve-out and re-platforming remain a key execution watchpoint.

SourceryEN · 57 min

Benchmark's AI Bets: Cerebras, Sierra, Legora, Fireworks, Starcloud, Gumloop..

Everett RandleMolly O'Shea

AI is breaking the spreadsheet playbook: billion-dollar businesses can still lack unit economics or durable differentiation, and scale may increase impairment risk.Inference monetization can drive revenue from 1 to 30 to 300, while agents shift purchases toward intelligence or economic output.Frontier labs retain pricing power if recursive self-improvement works, but face a 95%-as-good open-source squeeze if capabilities plateau.

SourceryEN · 104 min

The Anduril Thesis

Kyle HarrisonMolly O'Shea

Anduril challenges defense’s cost-plus, built-to-spec model with fixed-price, built-to-mission products for high-volume, low-cost, attritable conflict, where US munitions could last roughly 11 days.Lattice links Sentry Towers, Fury, Copperhead, and EagleEye’s $22 billion IVAS contract through sensor fusion; the small number of neo-primes makes execution and second-order beneficiaries worth monitoring.